Cited by 598Computational Drug Discovery MethodsPharmaceutical Economics and PolicyHistorical Medical Research and Treatments

The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.

Drug repurposing: a promising tool to accelerate the drug discovery process

Open access

Parvathaneni, Vineela, Kulkarni, Nishant S., Muth, Aaron, Gupta, Vivek·2019·Drug Discovery Today

DOI 10.1016/j.drudis.2019.06.014PMC PMC11920972

Open this paper in CoChat — free account

Abstract

Traditional drug discovery and development involves several stages for the discovery of a new drug and to obtain marketing approval. It is necessary to discover new strategies for reducing the drug discovery time frame. Today, drug repurposing has gained importance in identifying new therapeutic uses for already-available drugs. Typically, repurposing can be achieved serendipitously (unintentional fortunate observations) or through systematic approaches. Numerous strategies to discover new indications for FDA-approved drugs are discussed in this article. Drug repurposing has therefore become a productive approach for drug discovery because it provides a novel way to explore old drugs for new use but encounters several challenges. Some examples of different approaches are reviewed here.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2019.06.014

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
New uses for old drugs
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 996
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Tos, A. P. D., Kunkler, I. H., Otter, R., Licitra, L. F., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 813
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Phase II failures: 2008–2010
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 498
Phase III and submission failures: 2007–2010
Arrowsmith, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 438

Flagged first, then by citations

Show all 87 references

2 of the 87 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Repurposing drugs helps patients with rare diseases. Available at: https://www.elsevier.com/connect/repurposing-drugs-helps-patients-with-rare-diseases.
Sekhon, 2013, Repositioning drugs and biologics: retargeting old/existing drugs for potential new therapeutic applications, J. Pharm. Educ. Res., 4, 1

Sorted by citations

Items 501–598 of 598

Machine Learning-Enhanced Drug Repurposing Strategies for Cystic Fibrosis
Chauhan, R., Jena, M., & Kaur, H. (2025) · Lecture notes in networks and systems · doi:10.1007/978-981-96-4071-3_11
Bioinformatics tools for drug repurposing: a tutorial using heart failure as a case study
Fonseca, I., Trindade, F., Santos, M. J. D. S., Leite-Moreira, A. F., Moreira‐Gonçalves, D., Vitorino, R. M. P., Ferreira, R. M., & Nogueira‐Ferreira, R. (2025) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100460
RETRACTED: Repurposing Angiotensin II Receptor Blockers: Unlocking New Therapeutic Horizons
Chatzipieris, F. P., Mavromoustakou, K., Matsoukas, J., & Mavromoustakos*, T. (2025) · Journal of Cardiovascular Medicine and Cardiology · doi:10.17352/2455-2976.000230
Retracted
Discovery of Cyclopentane-Based Phospholipids as Miltefosine Analogs with Superior Potency and Enhanced Selectivity Against Naegleria fowleri
Hassan, A. H. E., Lê, H. G., Võ, T. C., Kim, M., No, J. H., Aboutaleb, M. H., Sim, J., Na, B., & Lee, Y. S. (2025) · Pharmaceuticals · doi:10.3390/ph18070984
Computational screening of repurposed drugs targeting lactoferrin for neurodegenerative diseases
Alrouji, M., Alshammari, M. S., Alhumaydhi, F. A., Shahwan, M. J., Sharaf, S. E., Alghamdi, S. S., Atiya, A., & Shamsi, A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251359648
“20 The application of computational technologies and interdisciplinary methodologies highlight its revolutionary capability within contemporary medical practice.”
Inferring anti-viral drugs using nonnegative matrix factorization with self-paced learning and hypergraph regularization
Tang, Y., Xie, Z., Fan, Y., Zhong, K., & Deveci, M. (2025) · Expert Systems with Applications · doi:10.1016/j.eswa.2025.129104
Respiratory System-Based In Vitro Antiviral Drug Repurposing Strategies for Sars-Cov-2
Genc, D., Katı, A., Mandal, A. K., Ghorai, S., Salami, H., ElHefnawi, S. N. K., & Altuntaş, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815238693125010008
Insights into Caspase-6 Mutations and Neuropathology in Huntington’s Disease and Psychiatric Disorders: A Structural Genomics and Drug Repurposing Approach
Hakami, M. A., Alsaiari, A. A., Hazazi, A., & Hassan, M. I. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05233-5
“Drug repurposing is the process of using drugs for a different disease other than the one it was initially developed; it has benefits like shorter time to market, cheaper, and safety records [20].”
IMPLEMENTING ARTIFICIAL INTELLIGENCE IN DRUG RESEARCH DEVELOPMENT
Obbalareddy, S., Shahi, S., & Dubey, A. (2025) · BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY · doi:10.58240/1829006x-2025.21.6-361 · Cited by 4
RePo-SUDOE: A Transnational Network for Drug Repurposing in the SUDOE Space
Filipe, H. A. L., Costa, A., Moreira, A. F., Miguel, S. P., Roque, F., Coutinho, P., Martínez-Rodríguez, L., Fernández-Edreira, D., Cedrón, F., Fernandez-Lozano, C., et al. (2025) · Drug repurposing · doi:10.58647/drugrepo.25.1.0004
Deploying the drug repurposing approach for the identification of selective monoamine oxidase-B inhibitors against neurological disabilities: an in Silico and in vitro approach
Mohany, M., Al-Rejaie, S. S., Babu, M. A., Singh, T. G., Alam, P., Fareed, M., & Bansal, N. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00652-x
Mechanistic Insights into Vorinostat as a Repositioned Modulator of TACE-Mediated TNF-α Signaling via MAPK and NFκB Pathways
Park, J. H., Yasir, M., Choe, J., Han, J., Han, E., Park, W. S., & Chun, W. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090720
“In recent years, drug repositioning has gained significant momentum as a strategic alternative to conventional de novo drug development [1–3].”
Structure‐Guided Repurposing of FDA‐Approved Drugs Targeting CCR2 for Immune Cell‐Mediated Neuropathic Pain
Suliman, M., Alsayari, A., Alshahrani, M. Y., Asiri, M., Abohassan, M., Sabah, Z. U., Alqahtani, S. S., & Wahab, S. (2025) · ChemistrySelect · doi:10.1002/slct.202503014
Exploring drug repurposing for PAK2 inhibition: a systematic virtual screening of FDA-approved drugs against cancer
Wahab, S., Alsayari, A., Majrashi, T. A., Almoyad, M. A. A., Assiri, R. A., Ahmad, W., & Chandra, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03516-w
“Another promising strategy that has gained momentum in the past few years is drug repurposing, which aims to identify new therapeutic applications of molecules that have previously been approved for safety and efficacy by the FDA [9].”
Exploring the Therapeutic Potential of Akt1 PH Domain Inhibitors: A Structure-Based Virtual Screening Approach with FDA-Approved Drugs
Ezzemani, W., Ahmad, S., Bakkali, F., & Benmoussa, A. (2025) · Lecture notes in networks and systems · doi:10.1007/978-3-032-01970-7_37
Design, synthesis and preliminary biological evaluation of novel carbamoyl pyridone derivatives as potent inhibitors of Crimean-Congo hemorrhagic fever virus
Zhang, R., Wu, F., Liu, K., Li, J., Liu, Y., Hú, Z., Wang, M., & Zhong, W. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118328
AI's Inroad into Medication Enhancement
-, S., Sharma, S., Singh, S., Govindarajan, S., & Sharma, A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324457125010008
Drug repurposing and small molecule screening for phospholipase A 2 inhibition in Naja species venoms: an integrated in silico and in vitro approach
Adeyi, A. O., Afolayan, F. I. D., Salaam, R. A., Ajisebiola, B. S., Adeyi, O. E., Ajala, T. O., & Okonji, R. E. (2025) · Toxin Reviews · doi:10.1080/15569543.2025.2591040
“One of the most cost-effective and swift approaches to identifying promising drug leads is drug repurposing (akinlalu et al. 2021). this involves identifying new uses for existing FDa-approved drugs with extensive safety and efficacy testing (Parvathaneni et al. 2019).”
Bone antiresorptives as potential chelators for iron overload diseases
Konno, J. T. L., & Espósito, B. P. (2025) · BioMetals · doi:10.1007/s10534-025-00777-4
In-vitro Methods for Drug Repurposing in AntiViral Therapy
Tirpude, N. V., & Sharma, A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898811143125010006
Clinical Trial of Repurposed Drugs for Antiviral Therapy
Jinta, P., Jhagta, C., Rana, S., Nagu, P., Bhardwaj, V. K., & Mehta, V. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898811143125010011
Synthetic Flozins in Cancer Prevention and Combination Strategies: Structural Insights and Therapeutic Potential
Zieliński, M., Michalak, O., Ruszczak, M., & Cybulski, M. (2025) · Molecules · doi:10.3390/molecules30244681
TNK2 promotes the EMT proliferation and invasion of esophageal squamous cell carcinoma by enhancing FOXO1 through the AKT pathway
Zhou, M., Yang, Y., Qiu, T., Wu, Y., Zhu, W., Xu, Z., Li, X., Huang, H., Ma, R., Lu, Y., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115939
Repositioning Imipramine for Antiparasitic Effects Against Giardia lamblia
Herrera-Valero, X. Z., Nery‐Flores, S. D., Gutiérrez‐Gutiérrez, F., Campos‐Múzquiz, L. G., Esparza‐González, S. C., Rodrı́guez-Herrera, R., & Palomo‐Ligas, L. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4040056
Additional file 1 of Two-point immobilization of M3 muscarinic receptor: a method for recognizing receptor antagonists in natural products
Huang, X., Wang, T., Wang, L., Sun, Y., Zhang, Z., & Zhang, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26715904
Additional file 1 of Topology-enhanced molecular graph representation for anti-breast cancer drug selection
Gao, Y., Chen, S., Tong, J., & Fu, X. (2022) · Figshare · doi:10.6084/m9.figshare.21171511
Review of medicines approved by the Food and Drug Administration from 2012 to 2024
Kurkin, D. V., Osadchenko, N. A., Bakulin, D. A., Morkovin, E. I., Voskresenskiy, S. A., Maltsev, D. V., Maltseva, M. O., Gorbunova, Y. V., Marincheva, O. V., Zvereva, V. I., et al. (2025) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2025-13-6-432-486
Reviviscence et repositionnement dans le cycle de vie d’un médicament
Bouvenot, G. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.09.008
Drug Repurposing Alchemy: Turning Scientific Discoveries into Lifesaving Realities
Rani, D., & Dey, S. K. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_42
Recent Advances in In-Silico Drug Repurposing: Leveraging Computational Tools for Enhanced Therapeutic Discovery
Patoliya, J., Thaker, K., & Joshi, R. G. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898812164125080004
Drug Repurposing: Harnessing the Therapeutics from Antidiabetic Molecules
Bhatta, A., Mahale, P., Baral, H., Yuvaraj, D. K., & Kaundal, R. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_3
Drug Repurposing for Autoimmune Disorders
Singh, N., Kanaujia, K. A., Verma, A., Alka, & Mishra, N. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_5
Challenges for Drug Repurposing: Special Emphasis on Regulatory and Patent Issues
Maheshwari, M., Ghosh, S., Ali, S., Shubham, K., Pal, M., Sahoo, P. K., & Behera, B. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_8
Drug Repurposing: Exploring Newer Therapeutic Potential
Pancholi, B., Rao, A., & Garabadu, D. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_7
3 Rs: Repurposing and Reformulation of Therapeutics
Kumari, M., Dwivedi, M., Pandey, A., & Chaurasia, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_9
Repurposing gut microbiota modulators: insights into current and novel applications
Mabrouk, R. R., Beshbishy, A. M., Elmalah, W. M., Elattar, O. M., & Noah, A. A. (2026) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-025-00727-6
“Pharmacological repurposing accelerates the discovery of new therapeutic applications for existing drugs, reducing both development time and costs [65].”
Molecular Insights Into Repurposed Drug Interactions With HDAC11 for Advancing Epigenetic Therapeutics in Cancer and Neurodegenerative Diseases
YANG, Y. G., Ahmed, K. A. M., Dinislam, K., Prasad, P., & Atiya, A. (2026) · Journal of Chemistry · doi:10.1155/joch/4628759
Computational identification of potential inhibitors for dominant proteins in Viperidae snakes from FDA-approved drugs
Adeyi, A. O., Afolayan, F. I. D., Salaam, R. A., Ajisebiola, B. S., Adeyi, O. E., Omolola, A. T., & Okonji, R. E. (2026) · Scientific African · doi:10.1016/j.sciaf.2026.e03215
AI and nanotechnology for advancing drug development
Roy, S. K., Ali, K. A., Saha, S., & Biswas, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34059-8.00014-2
Protective effects of linagliptin and tenofovir disoproxil fumarate against APAP-induced acute liver injury: A biochemical, histological, and computational study
Yamin, M., Ali, M., Mehreen, A., Akhtar, B., Alsaleem, M. A., Jamil, S., Al-Emam, A., & Hassan, H. M. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103374
ConvAHKG: Action-based hybrid knowledge graph with a dual-channel convolutional approach for drug repurposing
AghGhaleh, M. K., Abedian, R., Zarghami, R., Siahpirani, A. F., & Gharaghani, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-38656-8
Machine learning-driven computational drug repurposing to identify new tubulin inhibitors against cancer
Neelima, N., Elrewey, H., Sneha, S., Ruiz, A., Wahajuddin, M., Joshi, G., & Jha, V. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118587
Drug repositioning by belief networks and ensemble method
Le, M. H., Anh, D. N., & Dang, X. T. (2026) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ae43f0
Microbial pigments as potential anti-rift valley fever virus drugs
Farouk, F., Ibrahim, I. M., & Azzazy, H. M. E. (2026) · BMC Chemistry · doi:10.1186/s13065-025-01680-2
“Their chemical production is time consuming and expensive, posing a challenge even to countries with developed infrastructures [9, 10].”
Elbasvir triggers ferroptosis in esophageal squamous cell carcinoma through NCOA4-mediated ferritinophagy
Tang, M., Gong, F., Yang, M., He, S., Cheng, J., Yang, Z., Xu, L., Ma, Q., Guo, X., & Zhong, X. (2026) · Medical Oncology · doi:10.1007/s12032-026-03249-y
“Despite this, the overall treatment options are still scarce, and primary and acquired resistance to ICI remains a major obstacle in clinical practice [14, 15 ], which leads to limited long-term benefits for patients.”
Chorioallantoic membrane assay demonstrating pro-angiogenic properties of BRAF inhibitor: a tool to treat chronic wounds
Karhana, S., Sultana, Y., Saha, N., Nidhi, & Khan, M. A. (2026) · Growth Factors · doi:10.1080/08977194.2026.2632046
“Drug repurposing, which involves using existing medications for new therapeutic purposes, presents a promising strategy (Parvathaneni et al. 2019).”
Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment
Quadros, M., Rajana, N., & Gupta, V. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-025-03322-1
“This approach offers several advantages, including potentially reduced development costs, a well-characterized safety profile, and expedited regulatory approval [14].”
Self-citation
Steroids as antibacterials
Daab, A., Beal, D. M., Kemp, J., Robinson, G. K., & Shepherd, M. (2026) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2026.02.001
AI-driven network-based drug repurposing: A roadmap for precision medicine in Kyrgyzstan's and low and middle income countries' resource-limited healthcare systems
Siddiqui, M. F., Elbarazi, I., & Калматович, К. Р. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44430-2.00005-0
Evolution in the Method of Drug Repurposing - Past, Present, and Future, A Chronological Doctrine Journey
Talukder, P., Nandi, A., Sengupta, S., Das, S., & Sultana, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814533126010005
"The Intersection of AI and Medicine: Exploring the Future of Drug Repurposing"
Joshi, N., Joshi, H., Wadhwa, R., Joshi, N., Dhaundhiyal, K., & Gwasikoti, J. (2025) · International Conference on Artificial Intelligence and Speech Technology (AIST) · doi:10.1109/aist68591.2025.11441376
Structure-based drug repurposing reveals ponatinib and lapatinib as stable inhibitors of Aurora kinase B: Mechanistic insights from high-resolution molecular dynamics and free-energy analyses
Hasan, G. M., Ramesh, T., Mohammad, T., & Hassan, M. I. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109034
Interaction of the Hfq protein with the bacterial membrane and functional consequences on RNA export
Turbant, F. (2024) · theses.fr (ABES) · doi:10.70675/fab39073z4e57z4801zb257z92e432d393b4
Ion-Channel-Mediated Drug Repurposing Opportunities Validated by Single-Cell Perturbation in Colorectal Cancer
Dong, Z., Meng, X., & Wang, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083412
Cancer's nano-messengers: The mechanistic universe and therapeutic rewriting of tumor-derived exosomes
Anil, A. V., & Rajendran, K. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108440
Optimization and evaluation of Olmesartan medoxomil spanlastics for the management of epilepsy
Qushawy, M. K. E., Arafa, M. F., Alzahrani, S., Mortagi, Y. I., Shokr, M. M., & Elsherbiny, N. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108487
Applications and prospects of artificial intelligence and digital medicine in pediatric nasal skull base tumors
Wu, X., Wei, J., Liu, C., Wang, P. Y., 葛文彤, & Han, Y. (2026) · Pediatric Investigation · doi:10.1002/ped4.70068
“92,93 AI holds great potential in this area, as it facilitates the repurposing of existing anti-cancer drugs for new therapeutic applications.”
Sulfonylureas beyond diabetes: A comprehensive review on anticancer and off-target effects (1956–2025)
Tomczyk, M. D., Wawrzynosek, C., de Carrillo, D. G., Krzystanek, M., Pantziarka, P., & Jędrzejowska–Szypułka, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119009
Macrophage-derived FN1 orchestrates the radiation-induced abscopal effect in breast cancerPreprint
Jin, X., Li, L., Yu, B., Zhang, J., Feng, X., Jing, J., Tian, J., Gao, F., Di, C., Chen, W., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9662129/v1
Systematic Identification of Therapeutic Targets and Repurposed Drugs for Stroke: From Genome Causal Analysis to Multilevel Validation
Zhang, X., Zhang, Y., Li, J., Wang, W., Tu, W.-J., & Wang, H.-Q. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046088
“6,7 In recent years, significant progress has been made in the treatment of ischemic stroke.”
Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough
Ahuja, S., Kanwar, D., Silakari, P., Sahu, S. K., & Kaur, P. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-01013-y
A Denoising Adversarial Model Based on Hyperellipsoidal Knowledge Representation Learning for DTI Prediction
Yang, C., Xiong, F., Luo, Y., & Wang, F. (2026) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbbio.2026.3710670
Dihydroergotamine alleviates circadian rhythm disorders through predicted interaction with to CRY1
Cai, L., Sun, Y. W., Wang, S., You, Q., Xie, W., Zhang, J., & 李伯安 (2026) · Molecular Diversity · doi:10.1007/s11030-026-11652-w
FusionMa-DTA: Cross-Modal Fusion and Global-Local Sequence Modeling for Drug-Target Affinity Prediction
Zhang, X., Lan, W., Huang, T., & Huy, H. (2026) · Lecture notes in computer science · doi:10.1007/978-981-92-3719-7_21
Computational Discovery of Potential HDAC6 Inhibitors through Integrated Virtual Screening and Molecular Dynamics Approaches
Gonzalez, M., Ruiz, J., Torres, L., & Ruiz, E. (2026) · Pharmaceutical Sciences and Drug Design · doi:10.51847/n3qdrlsgru
Spiramide and Hydroquinidine Inhibit Proliferation and Migration While Promoting Apoptosis and Oxidative Stress in Neuroblastoma Cells
Gümüş, E., Keskin, İ., Yıldırım, E., Kavak, S., & Demircan, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146367
“These compounds have already undergone extensive safety and pharmacokinetic testing, significantly reducing the time and cost associated with drug development [5].”
A functional genomics-pharmacotranscriptomics framework identifies host-directed anti-influenza agents
Qiu, J., Xing, X., Wang, J., Yuan, W., Li, X., Wu, A., Gu, Z., Zhou, Z., & Wang, J. (2026) · iScience · doi:10.1016/j.isci.2026.116899
Integrative drug repositioning identifies FDA-approved inhibitors of HSP90AA1 with therapeutic potential in colorectal cancer
Li, X., Xu, S., Waqas, M., Zhang, H., Ouyang, D., & Huang, Z. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110262
AI-Driven Drug Repurposing Strategies for Precision Therapy in Breast Cancer
Jakkula, B. K., & Shyam, P. (2026) · Pharmaceutical science. · doi:10.5772/intechopen.1016336
Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis
Feng, Y., Han, Z., Shao, J., Caliskan, B., Shi, H., Du, L., Zhou, X., Qi, Y., Zhang, J., Hao, Z., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02373-4
ERP27 as a novel therapeutic target in Glioblastoma multiforme: Insights from a multi-faceted computational analysis
Prapa, P. M., Saba, A. A., Hosen, M. R., Bhattacharjee, P., Majumder, B. K., Palit, P., Guinto, M. C., & Sarker, P. K. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100529
Ai Driven Approaches in Drug Target Identification
khan, A., Siddiqui, F., Aggarwal, P., & Anas, M. (2026) · Innovations in Sustainable Technologies and Computing · doi:10.1007/978-3-032-22830-7_37
In silico and in vitro drug repurposing strategy for targeting dopamine receptor D2 in colorectal Cancer treatment
Qaravi, A., Gholizadeh, H., Abyazi, M. A., Khoncheh, A., & Heiat, M. (2026) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2026.100787
“25,26 These methods overcome the limitations of isolated experimental studies and accelerate the identification of safe and effective therapeutic candidates while reducing the risk of costly failures.”
In Silico approach for exploring the potential of few drugs against Leishmaniasis
Yadav, S., Kashid, S., Suttee, A., Kadam, P., & Kasarla, R. (2026) · AIP conference proceedings · doi:10.1063/5.0286192
Telmisartan Repurposing Targets Novel Biomarkers for Precision Colorectal Cancer Therapy
Hunachagi, S., Alqudihi, H. H., AbdulAzeez, S., Borgio, J. F., & Almohazey, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18081029
“The majority of the cost is saved in safety testing, molecular characterization, safety profiling and initial marketing [36,117,118].”
Identification of flupirtine as a candidate against liver fibrosis in mice: Preserving mitochondria quality by suppressing calpain 1/complex I/mtROS axis via targeting asparagine synthase
Rao, Y., Su, R., Fu, H.-L., Liu, J., Cao, W.-J., Yang, Z., Zhang, C., Su, X., Liu, F., Jiang, Z., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.017
Multilayered Silica‐Core/Chitosan‐Coated Nanostructures Co‐Delivering Tamoxifen and Quercetin Mitigate LPS ‐Associated Neurodegenerative and Alzheimer's Disease‐Like Alterations
Elwakil, B. H., Helal, A. M., El‐Khatib, M., Abdelnaser, A., Darwish, A. A.-E., Shehata, N. S., Akl, S. H., Moneer, E. A., Bakr, B. A., & Wakil, A. E. (2026) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.70150
The Battle Against Emerging Viruses
Rehman, S. U., Jahangir, A., & Hussain, M. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9276-8.ch007
Repurposing butoconazole as a GRP78 substrate-binding domain (SBD) inhibitor to induce endoplasmic reticulum stress–mediated apoptosis in triple-negative breast cancer
Song, Y., Yuan, Z., Li, Z., Huang, Y., Lu, Y., Yang, Q., Wang, Y., Zhang, L., & Ma, W. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110447
Advances in Multimodal Deep Learning for Drug Repurposing
Zhang, Y.-L., Qian, M.-Y., Wang, C.-Y., & Chen, Z. (2026) · AI · doi:10.3390/ai7090335
“These potential time and cost advantages have contributed to sustained interest in drug repurposing across therapeutic areas [4].”
Bovine Serum Albumin Nanoparticles Prepared with Genipin: Size Modulation, Encapsulation, and In Vitro Response
Teixeira, B., Almeida, M., Frazão, C., Girao, A. V., Pais, A. C. S., Santos, S. A. O., Oliveira, M., & Pinto, R. J. B. (2026) · Nanomaterials · doi:10.3390/nano16171086
Analysis of polypeptide derivati1ves targeting the melanocortin-4 receptor for treating hypoactive sexual desire disorder
Oyebamiji, A. K., Akintelu, S. A., Ebenezer, O., AKINTAYO, E. T., Akintayo, C. O., & Afolabi, S. O. (2026) · Eclética Química · doi:10.26850/1678-4618.eq.v51.2026.e1648
72120 Role of cross-coupling reactions in drug discovery and development
Jalli, D. P., Rallabandi, N. C., & Kumar, R. (2026) · De Gruyter eBooks · doi:10.1515/9783111850825-021
Leveraging neural network models for drug repurposing: a case study on cardiac hypertrophy
Magnusson, R., Johansson, M., Hagvall, S., & Synnergren, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-68286-z
“Different strategies are described in the literature to perform drug repurposing 10–14 , and these can be classified into experimental - or computational approaches.”
Influential
An AI-Driven Chemogenomics Knowledgebase for Human-Transmissible Pathogens: A Platform for Antimicrobial Drug Discovery
Kang, J., Zhu, L., Li, H., Xie, X., Liu, C., Feng, Z., Wang, Y., Mo, O., 王成素, Li, X., et al. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c02102
Structure-based drug repurposing and in vitro evaluation of VAV2-associated candidates for suppression of macrophage foam-cell formation in atherosclerosis
Bansal, P., & Srivastava, K. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11713-0
Newly Identified FDA-Approved MTAs: Opportunities for Antimicrobial Repurposing?
Zinai, A. Z. R., Gaye, M., Baksheeva, V. E., Fenollar, F., Tsvetkov, P. O., & Mediannikov, O. (2026) · Biochemistry (Moscow) · doi:10.1134/s0006297926601504
Design, Synthesis, and Anti-Inflammatory Activity Evaluation of Novel thieno[2,3- d ]Pyrimidin-4(3 H )-One-Based NLRP3 Inflammasome Inhibitors
Jiang, Y., Sun, S., Liu, J., Huang, J., Wang, H., Xu, T., Wang, L., 釋真地, & Li, X. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02162
PEARL: novel protein targets recommendation model via heterogeneous graph representation learning
Liu, Z., Luan, J., Zhang, Z., tang, K., Qin, X., Qi, Z., Zhang, B., & Liao, J. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag551
“As a promising solution, drug repurposing offers a more efficient and cost-effective pathway by identifying new therapeutic indications for existing approved drugs [ 6, 7].”
Target-centric drug repurposing: a next-generation approach to confront antimicrobial resistance
Gogoi, I., Saikia, S., & Chetia, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44748-8.00024-5
BindingDB Entry 50018480: A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.
BindingDB (2024) · UC San Diego · doi:10.7270/q2639tzd
BindingDB Entry 50021016: Identification of the exosomal PD-L1 inhibitor to promote the PD-1 targeting therapy of gastric cancer.
BindingDB (2025) · UC San Diego · doi:10.7270/q2v69q67
BindingDB Entry 50020720: Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.
BindingDB (2024) · UC San Diego · doi:10.7270/q2gb28h6
BindingDB Entry 50021949: New insights into butyrylcholinesterase: Pharmaceutical applications, selective inhibitors and multitarget-directed ligands.
BindingDB (2025) · UC San Diego · doi:10.7270/q24172rj
BindingDB Entry 50022142: Structure-based screening, optimization and biological evaluation of novel chrysin-based derivatives as selective PPARγ modulators for the treatment of T2DM and hepatic steatosis.
BindingDB (2025) · UC San Diego · doi:10.7270/q2wm1k5j
BindingDB Entry 50005593: A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects.
BindingDB (2026) · UC San Diego · doi:10.7270/q2tb1cqv
BindingDB Entry 50020770: Drug repurposing of propafenone to discover novel anti-tumor agents by impairing homologous recombination to delay DNA damage recovery of rare disease conjunctival melanoma.
BindingDB (2024) · UC San Diego · doi:10.7270/q2tf02vk
Structure-Based Virtual Screening Identifies Sonidegib and Radotinib as Potential SPIN1 Inhibitors for Anticancer Drug Repurposing
Khuzin, D., Khan, M. S., Alokail, M., Zuberi, O., & Zuberi, A. (2026) · Pharmaceuticals · doi:10.3390/ph19111693

Authors: Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V.
Affiliations: St. John's University (US)
Corresponding author: Gupta, Vivek
ORCID: Parvathaneni, Vineela
Muth, Aaron
Gupta, Vivek
Venue: Drug Discovery Today
Publisher: Elsevier BV
Published: 2019-10
Volume: 24
Issue: 10
Pages: 2076-2085
ISSN: 1359-6446 (ISSN-L)
DOI: 10.1016/j.drudis.2019.06.014
PMC: PMC11920972
OpenAlex: W2951512731
Semantic Scholar: 023e169dfa4fe591ef24cf91b93e0d7371bb3400
Cited by: 597
References: 87
Citations by year: 2026: 80 · 2025: 137 · 2024: 130 · 2023: 96 · 2022: 77 · 2021: 52 · 2020: 22 · 2019: 3
FWCI: 3.18
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Drug Discovery Today (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Figshare (submittedVersion, cc-by)
Health Research Alliance (cc-by)
Funders: NIH (1R15HL138606-01A1)
American Heart Association (18AIREA33960072)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
Keywords: drug repurposing, FDA-approved drugs, new therapeutic indications, serendipitous drug discovery, drug development challenges
MeSH terms: Humans, Drug Discovery, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug repurposing: a promising tool to accelerate the drug discovery process

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks